Tuesday, July 1, 2025 7/1/2025

Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection

Award Number: R01AI181701
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/21/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection - PROJECT SUMMARY TB remains the leading cause of death in HIV-infected persons, with one in four deaths attributable to TB. While the majority of healthy individuals infected with Mycobacterium tuberculosis (Mtb) control infection, co-infection with HIV increases the risk of progressing to TB disease by over 20 fold. Antiretroviral therapy (ART) decreases the incidence of ATB and remains the cornerstone of HIV care. However, the incidence of TB in HIV-co-infected individuals remains four-to-seven-fold higher after ART than in HIV-uninfected people in TB-endemic settings, regardless of the duration of ART or attainment of high CD4+ T cell counts. We have developed macaque models of Mtb/HIV co-infection which utilize ART. Depending on the timing of ART-intervention, SIV replication in the periphery as well as tissues is either effectively inhibited or not, recapitulating the whole spectrum of human tissue-specific and clinical outcomes. This allows for detailed longitudinal and mechanistic studies that are not possible in humans. Our data shows a clear role for indole 2,3, dioxygenase (IDO) in both the inhibition of effective immunity to TB as well as in orchestrating chronic immune activation in SIV-infected macaques. Blockade of IDO pathway improves the outcome of TB and HIV in singly infected macaques. Here, we will use inhibition approaches in the RM models of Mtb/SIV/ART to test the hypothesis that this will improve anti-TB immune responses, inhibit HIV-induced chronic immune activation, thus allowing the immune system to better control the co-infection. Our proposed studies will provide unprecedented novel insights into the molecular mechanisms that mediate reactivation of TB in the setting of HIV infection, and identify protective immune mechanisms that will inform the development of new treatment regimens and vaccines for TB.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $905,874 )
2025	2025	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Allergy and Infectious Diseases Research	000	2	5/1/2025	NON-COMPETING CONTINUATION	$905,874
														Subtotal = $905,874

Issue Date FY: 2024 ( Subtotal = $914,927 )
2024	2024	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Allergy and Infectious Diseases Research	001	1	9/12/2024	NEW	$91,493
2024	2024	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Allergy and Infectious Diseases Research	000	1	6/21/2024	NEW	$823,434
														Subtotal = $914,927

Grand Total All Awards = $1,820,801

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection

Award Number: R01AI181701

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/21/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer